A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-14
DOI
10.1038/s41416-020-01180-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy
- (2020) Andrew Antolic et al. JCI Insight
- The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
- (2019) Jérôme Piquereau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
- (2018) K A Blum et al. ANNALS OF ONCOLOGY
- Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors
- (2018) Mahalakshmi Ramadoss et al. DRUG DISCOVERY TODAY
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era
- (2018) Harmke J. Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
- (2018) Bjoern Chapuy et al. NATURE MEDICINE
- Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
- (2018) Afua A. Mensah et al. HAEMATOLOGICA
- A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry.
- (2018) Nicole Grace Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
- (2017) Michele Cioffi et al. Oncotarget
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- The world of protein acetylation
- (2016) Adrian Drazic et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- AMPK–ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells
- (2016) Ji Eun Jang et al. CLINICAL CANCER RESEARCH
- The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
- (2016) Yufang Ma et al. CLINICAL CANCER RESEARCH
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
- (2016) S. J. Hogg et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Targeting BET bromodomain proteins in solid tumors
- (2016) Vaibhav Sahai et al. Oncotarget
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
- (2016) Yue Zhao et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Beating the odds: BETs in disease
- (2015) Chen-Yi Wang et al. TRENDS IN BIOCHEMICAL SCIENCES
- GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
- (2015) Krishan Kumar et al. Scientific Reports
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
- (2014) A. M. Petrich et al. BLOOD
- Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
- (2014) S. E. Trabucco et al. CLINICAL CANCER RESEARCH
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
- (2014) C. A. French et al. Cancer Discovery
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
- (2013) A R Grayson et al. ONCOGENE
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation